Any current/future new fundraising through debt or equity?

There is no specific mention of any current or upcoming fundraising through debt or equity in the provided transcript. The company recently completed an IPO, which has boosted their business and helped fund growth. Expansion plans include increasing bed capacity and new hospital units, such as the upcoming Valsad unit. The company is focusing on internal growth, service enhancement, and acquisitions like Tulip Health. No explicit statements were made regarding raising new debt or equity funds at this time.

Any current/future capex/capital investment/strategic investment?

Maitreya Medicare Limited is planning to expand its current hospital at Vesu, Surat, potentially adding 70 to 80 beds depending on specialty and services. The upcoming Valsad unit has received building usage permission; hospital license is expected soon to start operations. Equipment for Valsad unit is already ordered and being installed. Expansion opportunities are being explored beyond Maharashtra and Gujarat. Acquisition of Tulip Health has been made, focusing on preventive and rehabilitative care including elderly care and advanced diagnostics. Future capex includes adding advanced tertiar

Future growth expectations in sales/revenue/volumes?

Maitreya Medicare expects a 20%-25% year-on-year revenue growth in existing hospitals over the next 2-3 years. Plans include increasing services and expanding bed capacity by 70 to 80 beds, depending on specialty and service design. Expansion of the current Vesu, Surat unit and upcoming Valsad unit are part of growth strategy. The company aims to introduce more advanced tertiary and quaternary care services like organ transplant, robotic surgeries, and high-end radiotherapies. These high-end services are expected to significantly increase the Average Revenue Per Occupied Bed (ARPOB), targeting

Future growth expectations in earnings/operating earnings/profits/EPS?

Expecting 20%-25% year-on-year revenue growth in existing hospitals driven by increased services and bed expansion (70 to 80 beds). Future expansions planned with the upcoming Valsad unit and other opportunities to increase capacity. ARPOB (Average Revenue Per Occupied Bed) projected to increase by at least 30%, aiming to reach around Rs. 40,000 with addition of advanced tertiary and quaternary care services like organ transplant and robotic surgeries. Highest ever quarterly result recorded in Q3 FY24 with 34% year-on-year revenue growth. PAT (Profit After Tax) positive at Rs. 1.57 crores with

Maitreya Medica.Q3 FY24Healthcare Services

Maitreya Medica. Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹125Market Cap: ₹85 CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Maitreya Medicare expects a 20%-25% year-on-year revenue growth in existing hospitals over the next 2-3 years.
Plans include increasing services and expanding bed capacity by 70 to 80 beds, depending on specialty and service design.
Expansion of the current Vesu, Surat unit and upcoming Valsad unit are part of growth strategy.
The company aims to introduce more advanced tertiary and quaternary care services like organ transplant, robotic surgeries, and high-end radiotherapies.
These high-end services are expected to significantly increase the Average Revenue Per Occupied Bed (ARPOB), targeting around Rs. 40,000.
Additional opportunities for capacity expansion are being explored as they arise.

Margin guidance

Category 3

Expecting 20%-25% year-on-year revenue growth in existing hospitals driven by increased services and bed expansion (70 to 80 beds).
Future expansions planned with the upcoming Valsad unit and other opportunities to increase capacity.
ARPOB (Average Revenue Per Occupied Bed) projected to increase by at least 30%, aiming to reach around Rs. 40,000 with addition of advanced tertiary and quaternary care services like organ transplant and robotic surgeries.
Highest ever quarterly result recorded in Q3 FY24 with 34% year-on-year revenue growth.
PAT (Profit After Tax) positive at Rs. 1.57 crores with a 13% PAT margin, turning around from negative in the previous year.
EPS (Earnings Per Share) increased to 2.84 post bonus share issuance.
Sustained ARPOB growth expected due to introduction of advanced services and better revenue mix.

See what Maitreya Medica. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no specific mention of any current or upcoming fundraising through debt or equity in the provided transcript.
The company recently completed an IPO, which has boosted their business and helped fund growth.
Expansion plans include increasing bed capacity and new hospital units, such as the upcoming Valsad unit.
The company is focusing on internal growth, service enhancement, and acquisitions like Tulip Health.
No explicit statements were made regarding raising new debt or equity funds at this time.

Order book

The transcript provided does not explicitly mention the current or expected order book or pending orders for Maitreya Medicare Limited. The discussion mainly revolves around: - Hospital bed size plans (typically 70 to 100 beds, sometimes 50 to 70 based on potential). - Expansion plans including the upcoming Valsad unit and possible further capacity increases. - Focus on increasing advanced tertiary and quaternary care services to boost Average Revenue Per Occupied Bed (ARPOB). - Revenue mix balancing between insurance schemes and out-of-pocket payments. - No direct references to order book or pending orders data. Therefore, there is no direct information on current or expected order book/pending orders in the transcript from the earnings call dated February 14, 2024.

See what Maitreya Medica. management said on order book — free account, 30 seconds.

Capex plans

Yes

Maitreya Medicare Limited is planning to expand its current hospital at Vesu, Surat, potentially adding 70 to 80 beds depending on specialty and services.
The upcoming Valsad unit has received building usage permission; hospital license is expected soon to start operations.
Equipment for Valsad unit is already ordered and being installed.
Expansion opportunities are being explored beyond Maharashtra and Gujarat.
Acquisition of Tulip Health has been made, focusing on preventive and rehabilitative care including elderly care and advanced diagnostics.
Future capex includes adding advanced tertiary and quaternary care services like organ transplants, robotic surgeries, and high-end radiotherapies to increase ARPOB.
Expansion plans are based on area need-based studies with typical bed size per hospital between 50 to 100 beds.

Track Maitreya Medica. — get its next earnings analysis in your feed

How does Maitreya Medica. rank vs peers in Healthcare Services?

Pro feature

ThisMaitreya Medica.

Rev 2Mar 3

See where Maitreya Medica. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Maitreya Medica. rank in Healthcare Services?

Compare Maitreya Medica. against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Maitreya Medica.'s management said in earlier quarters

Others in Healthcare Services this season

Rainbow Childrens Medicare Ltd (Q2 FY27)
Year-on-year (YoY) growth in revenue: 23.2% . Key investor presentation takeaways from Rainbow Childrens Medicare Ltd's Q2 FY27 investor presentation — and how
Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio

Compare:vs Apollo Hospitals Enterprise Ltd vs Manipal Health Enterprises Ltd vs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →